Loading
Paper cited by one bottleneck page and 22 idea pages, indexed on Europe PMC as PubMed record 33820998 and published in Nature Medicine; the citing pages link this DOI, which is how the record was matched.
Europe PMC indexes no abstract for this record; the title is the only text available.
Indexed on Europe PMC as PubMed record 33820998 (DOI 10.1038/s41591-021-01312-x). Matched by DOI alone: one bottleneck page and 22 idea pages cite this DOI among their external links (the pages are listed under Related), and this page was written so that the citation resolves inside OnCo. No figure has been checked by an editor.
One bottleneck page and 22 idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Shares A liability framework for clinical AI: safe harbour for clinicians, liability for makers, Patients told which AI is used in their care, in plain language, Rules for retiring cancer AI when performance drops or the standard of care moves, Mandatory post-market performance reporting for cancer AI.
Shares A neutral public evaluator for cancer AI, on the model of NIST, Red-team programmes that attack cancer AI before patients do, External validation at five or more sites in two countries before clearance, AI that is built but not validated or deployed.
Shares Digital twins for treatment selection, validated by predicting before observing, Whole-patient digital twins validated in prospective randomised trials, A pre-competitive consortium to train a shared multimodal cancer foundation model, AI that is built but not validated or deployed.
Shares A standard evaluation pathway for AI-assisted pathology, from reader study to deployment, A pre-competitive consortium to train a shared multimodal cancer foundation model, AI that is built but not validated or deployed.
Shares Pay for cancer AI only when it has outcome evidence, then pay properly, AI that is built but not validated or deployed.
Shares A standard evaluation pathway for AI-assisted pathology, from reader study to deployment, A pre-competitive consortium to train a shared multimodal cancer foundation model, AI that is built but not validated or deployed.
Shares A randomised trial of AI-generated treatment recommendations versus tumour boards, AI that is built but not validated or deployed.
Shares In silico trials to prioritise combinations, scored against later real trials, AI that is built but not validated or deployed.